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ABSTRACT
Background: Multicentric Castleman disease (MCD) is a rare, systemic 
lymphoproliferative disorder driven by interleukin (IL)-6 overproduction. Siltuximab, 
an anti-IL-6 monoclonal antibody, has demonstrated durable tumor and symptomatic 
responses in a multinational, randomized, placebo-controlled study of MCD. 
Methods: This preplanned safety analysis was conducted to evaluate the long-
term safety of siltuximab treatment among 19 patients with MCD who had stable 
disease or better and were enrolled in a phase-1 study and subsequent ongoing, open-
label, phase-2 extension study. Dosing was 11 mg/kg administered intravenously 
every 3 weeks, per protocol, or every 6 weeks at the investigator’s discretion. Safety 
monitoring focused on potential risks associated with the anti-IL-6 mechanism of 
action. Investigator-assessed disease control status was also documented. 
Results: Median treatment duration for the 19 patients was 5.1 (range 3.4, 7.2) 
years, with 14 (74%) patients treated for >4 years. Grade-≥3 adverse events (AEs) 
reported in >1 patient included hypertension (n = 3) and nausea, cellulitis, and fatigue 
(n = 2 each). Grade-≥3 AEs at least possibly attributed to siltuximab were leukopenia, 
lymphopenia, and a serious AE of polycythemia (n = 1 each). Hypertriglyceridemia 
and hypercholesterolemia (total cholesterol) were reported in 8 and 9 patients, 
respectively. No disease relapses were observed, and 8 of 19 patients were able to 
switch to an every-6-week dosing schedule. 
Conclusions: All MCD patients in this extension study have received siltuximab 
for a prolonged duration (up to 7 years) without evidence of cumulative toxicity or 
treatment discontinuations and with few serious infections. All patients are alive, 
demonstrate sustained disease control, and continue to receive siltuximab.
INTRODUCTION
Multicentric Castleman disease (MCD) is a rare 
lymphoproliferative disease driven by dysregulation of the 
cytokine interleukin (IL)-6 [1]. At the time of performance 
of the current study, no standard of care was established 
for MCD [2]. Systemic manifestations of MCD include 
fever, fatigue, night sweats, wasting, weight loss, and 
loss of appetite [3]. While clinical manifestations vary, 
enlargement of multiple lymph nodes and laboratory 
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abnormalities (eg, anemia, hypoalbuminemia, and elevated 
acute-phase proteins) are common [1, 4]. Treatment 
with siltuximab, an anti-IL-6 monoclonal antibody 
with high affinity for human IL-6, has demonstrated 
efficacy in patients with Castleman disease treated in 
a phase 1 clinical trial [5, 6]. More recently, results 
from a randomized, double-blind, placebo-controlled 
study confirmed that siltuximab treatment can yield 
durable tumor and symptomatic responses, resolution 
of anemia, and improvement in inflammatory disease 
parameters in patients with MCD [7] and led to the recent 
approvals from the Unites States (US) Food and Drug 
Administration [8] and European Commission [9] of 
siltuximab for the treatment of patients with MCD who 
are human immunodeficiency virus (HIV) negative and 
human herpesvirus-8 (HHV-8) negative.
In phase 1 evaluations, the siltuximab safety profile 
was consistent across all dose levels tested. Thus, a 
recommended dose of 11 mg/kg was determined based 
on efficacy and adequate suppression of C-reactive 
protein (CRP) at that dose level. In the aforementioned 
randomized study [7], the incidences of grade-≥3 adverse 
events (AEs) and serious adverse events (SAEs) were 
similar between siltuximab and placebo. The most 
commonly reported grade-≥3 AEs included fatigue (9%) 
and night sweats (8%); infusion reactions were relatively 
infrequent (8%) and generally of low grade (1 anaphylactic 
reaction led to siltuximab discontinuation) [7]. This safety 
profile, however, relates to median treatment durations of 
8.5 (range 0.03, 60.5) months (phase 1) [5] and 12.3 (range 
0.03, 33.9) months (randomized study) [7]. Thus, this 
long-term extension study provides a unique opportunity 
to characterize the long-term safety profile of treatment 
with siltuximab in patients with MCD.
RESULTS
Baseline characteristics and disposition
Between April 2011 and January 2013, 19 of the 37 
patients with MCD from the previous phase 1 siltuximab 
study [5] were enrolled in the study extension and continued 
to receive siltuximab at 4 US sites. When these patients 
initially commenced siltuximab treatment in the phase 1 
study, the median age was 44 (range 18, 76) years and the 
median disease duration was 4.8 months (37% of patients 
were newly diagnosed). Among the 12 patients with prior 
systemic therapy, rituximab (n = 8) and corticosteroids (n 
= 6) were the most commonly used (Table 1). Of these 19 
patients, 10 (53%) had hyaline vascular and 9 (47%) had 
plasmacytic histological subtype. Five patients had a body 
mass index (BMI) >40 when entering the extension study, 
and an additional 3 had a BMI >30.
At the time of enrollment in the extension study, 
the 19 participating patients had received a median of 58 
(range 29, 97) doses of siltuximab over a median of 3.3 
(range 1.6, 5.0) years while in the phase 1 study. From the 
start of the phase 1 study to the data cutoff for the current 
interim analysis (January 2013), these patients received 
a median of 81 (range 49, 129) doses of siltuximab over 
a median of 5.1 (range 3.4, 7.2) years, with 14 (74%) of 
patients treated for longer than 4 years. At the time of the 
analysis, 11 patients received treatment at q3wks dosing and 
8 patients received treatment at q6wks dosing (for 1 patient, 
this meant a continuation of the dosing interval within 
the phase 1 study). Among these 8 patients, the median 
treatment duration on the extended (q6wks) dosing interval 
was 11 months (range 5.8 months to 3.8 years). Of note, 1 
additional patient started in this study with 4 cycles q6wks 
dosing and continued with q3wks dosing. All 19 patients are 
alive and continue to receive siltuximab treatment.
Safety
Over the combined time course of the phase 1 and 
extension studies (median 5.1 years; range 3.4, 7.2 years), 
all patients reported at least 1 AE of any grade, with 
upper respiratory tract infection (90%); nausea (63%), 
vomiting (58%); diarrhea (53%); hypercholesterolemia 
(total cholesterol; 47%); and pain in extremities, 
hypertriglyceridemia, headache, rash, and hepatic function 
abnormal (42% each) being the most commonly reported 
(Figure 1). The most common AEs ( >20%) reported in 
the extension study alone were upper respiratory tract 
infection (63%); diarrhea (32%); and fatigue, arthralgia, 
and pain in extremities (21% each). Those considered 
at least possibly attributed to siltuximab were reported 
in 6 patients during the extension study and included 
pneumonia, tooth abscess, constipation, increased 
hemoglobin, hypertriglyceridemia, hyperbilirubinemia, 
chronic otitis media, and upper respiratory tract infection 
(5% each) and grade-3 leukopenia and lymphopenia (5% 
each). When assessed by length of patient treatment/
follow-up, the incidences of AEs for the different system 
organ classes were similar or lower during the treatment 
periods of 2–4 years and >4 years when compared with 
the initial 2 years of treatment (Table 2). In most patients, 
the highest grade of AE reported was either grade 2 
(37%) or grade 3 (53%); 2 (11%) patients had a grade-4 
AE. Grade-≥3 AEs were most commonly reported in the 
following system organ classes: gastrointestinal, 6 (32%); 
infections, 5 (26%); blood/lymphatic system, 4 (21%); 
and general disorders/administration-site, 4 (21%). Most 
grade-≥3 AEs were each reported in only 1 patient; 
exceptions included 3 (16%) patients with hypertension 
and 2 (11%) patients each with nausea, cellulitis, and 
fatigue. No patient developed an infusion-related reaction, 
nor did any patient develop antibodies against siltuximab 
during the extension study.
Also for the combined phase 1 and extension 
studies, 5 (26%) patients had SAEs, including 3 (16%) 
patients with SAEs during the extension study. Two of 
these SAEs (syncope and dyspnea) were considered 
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unrelated to siltuximab, and 1 SAE (polycythemia) was 
considered at least possibly attributed to siltuximab. 
Twenty days after the third dose of siltuximab in the 
extension study (and also following 31 doses in the phase 
1 study), a male patient developed grade-3 secondary 
polycythemia (hemoglobin of 18.8 g/dL). This SAE 
led to hospitalization, resolved with hydration and anti-
coagulation treatment without complications, and did not 
recur despite continued siltuximab treatment. Following a 
3-week dose delay, this patient continued siltuximab and 
has received 25 cycles (total of 56 doses including phase 
1 exposure) as of the cut-off date for this safety analysis.
Nine (47%) patients had a dose delay due to an AE, 
4 of which occurred during the extension study and 1 of 
which was due to an AE possibly attributed to siltuximab; 
no patient discontinued siltuximab due to an AE.
Infections, hyperlipidemia, neutropenia, thrombocy-
topenia, gastrointestinal perforations, infusion-related 
reactions, and liver function abnormalities were further 
analyzed as AEs of interest in this long-term safety analysis 
(Table 3). Most infections were low-grade. Common 
infections, irrespective of grade, for the extension study 
were upper respiratory tract infection (63%), sinusitis 
(11%), nasopharyngitis (11%), and pneumonia (11%). 
Two (11%) of the extension-study patients reported 1 or 
more serious infections during the phase 1 study (abscess 
limb, cellulitis, device-related infection, peritoneal 
infection, pyelonephritis, vulval abscess, staphylococcal 
wound infection); no serious infections were reported 
during the extension study. No unusual viral infections 
or reactivations were observed; 7 (37%) patients had—
and are currently receiving—prophylactic acyclovir or 
valacyclovir; 5 (26%) patients were receiving antivirals 
at baseline, prior to any siltuximab treatment, and 6 (32%) 
were receiving antiviral prophylaxis during the extension 
study. Similarly, no opportunistic fungal infections were 
seen. Across the combined phase 1 and extension studies, 
the overall incidence of grade-≥3 serious infections was 
0.02 per patient-year.
Although hypercholesterolemia (total choles terol; 
47%) and hypertriglyceridemia (42%) were common 
among these 19 patients during the phase 1 study, these 
elevations were low-grade (9 grade-1 hypercholesterolemia; 
5 grade-1 and 3 grade-2 hypertriglyceridemia); 1 patient had 
Table 1: Patient demographic and disease characteristics at start of initial siltuximab treatment
Extension study patients (N = 19)
Male 12 (63)
Race
 Caucasian 16 (84)
 Black 1 (5)
 Asian 2 (11)
Age, years 44 [18, 76]
Weight, kg 83.5 [55.4, 169.8]
Disease duration, months 4.8 [1.3, 93.2]
Newly diagnoseda 7 (37)
Karnofsky performance status score 80 [60, 100]
Histology
 Hyaline vascular 10 (53)
 Plasmacytic 9 (47)
Prior therapy
 Cancer-related surgery 4 (21)
 Systemic therapy 12 (63)
  Rituximab 8 (42)
  Corticosteroid 6 (32)
  Thalidomide 2 (11)
  Cyclophosphamide 1 (5)
Data presented as n (%) or median [range].
aPatients who had not received any prior systemic therapy.
Oncotarget30411www.impactjournals.com/oncotarget
Figure 1: Adverse events considered at least possibly attributed to siltuximab for those events reported by ≥10% of 
patients across both the phase 1 and extension studies (n = 19). aIn addition, the adverse events of bone pain, herpes zoster, 
lymphopenia, rectal abscess, anal fistula, cardiac disorder, mitral valve incompetence, oral candidiasis, sinus bradycardia, chronic otitis 
media, irritable bowel syndrome, urobilinogen urine, decreased blood immunoglobulin M, and infusion-related reaction (5% each) and a 
serious adverse event of polycythemia (5%) were also considered at least possibly attributed to siltuximab.
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Table 2: Frequently reporteda adverse events by system-organ class and number of years of treatment
Years of siltuximab treatment
0 < Year ≤ 2 2 < Year ≤ 4 > Year 4
Treated patients 19 19 14
Patients with adverse events 19 (100) 19 (100) 13 (93)
 Infections and infestations 16 (84) 18 (95) 11 (79)
  Upper respiratory tract infection 10 (53) 10 (53) 8 (57)
  Nasopharyngitis 2 (11) 3 (16) 4 (29)
  Urinary tract infection 5 (26) 2 (11) 1 (7)
  Sinusitis 5 (26) 5 (26) 0
 Gastrointestinal disorders 14 (74) 13 (68) 7 (50)
  Diarrhea 8 (42) 5 (26) 5 (36)
  Nausea 10 (53) 5 (26) 1 (7)
  Musculoskeletal and connective tissue 
disorders 14 (74) 7 (37) 7 (50)
  Back pain 3 (16) 1 (5) 4 (29)
  Pain in extremity 7 (37) 1 (5) 4 (29)
  Arthralgia 6 (32) 4 (21) 2 (14)
  General disorders and administration site 
conditions 9 (47) 7 (39) 5 (36)
 Metabolism and nutrition disorders 14 (74) 8 (42) 5 (36)
  Hypertriglyceridemia 7 (37) 4 (21) 1 (7)
  Hyperuricemia 4 (21) 5 (26) 1 (7)
  Hypercholesterolemia 9 (47) 2 (11) 0
 Skin and subcutaneous tissue disorders 9 (47) 6 (32) 5 (36)
  Rash 5 (26) 5 (26) 1 (7)
 Eye disorders 2 (11) 3 (16) 4 (29)
 Nervous system disorders 11 (58) 7 (37) 4 (29)
  Headache 6 (32) 4 (21) 2 (14)
  Respiratory, thoracic, and mediastinal 
disorders 10 (53) 7 (37) 4 (29)
 Vascular disorders 8 (42) 3 (16) 4 (29)
 Hepatobiliary disorders 8 (42) 6 (32) 3 (21)
  Hepatic function abnormal 8 (42) 3 (16) 0
 Blood and lymphatic system disorders 8 (42) 6 (32) 2 (14)
  Thrombocytopenia 5 (26) 1 (5) 0
 Ear and labyrinth disorders 5 (26) 1 (5) 2 (14)
 Investigationsb 7 (37) 6 (32) 2 (14)
  Injury, poisoning, and procedural 
complications 7 (37) 5 (26) 1 (7)
(Continued )
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Years of siltuximab treatment
0 < Year ≤ 2 2 < Year ≤ 4 > Year 4
 Psychiatric disorders 5 (26) 2 (11) 1 (7)
 Renal and urinary disorders 5 (26) 3 (16) 1 (7)
Data presented as n (%).
aReported by ≥ 25% of patients during 0 to 2, > 2 to 4, or > 4 years of treatment.
bRefers to the Medical Dictionary for Regulatory Activities system-organ class category for the names and qualitative 
results (eg, increased, decreased, normal, abnormal, present, absent, positive, negative) of investigations, including clinical 
laboratory test concepts (eg, biopsies), radiologic test concepts, physical examination parameters, and physiologic test 
concepts (eg, a pulmonary function test).
(Continued )
Table 3: Frequently reporteda adverse events by system-organ class and study period
Study periodb
Phase 1 (n = 19) Extension (n = 19) Combined (n = 19)
All Grades Grade ≥ 3 All Grades Grade ≥ 3 All Grades Grade ≥ 3
 Patients with adverse events 19 (100) 10 (53) 19 (100) 8 (42) 19 (100) 12 (63)
 Infections and infestations 17 (90) 5 (26) 17 (90) 0 19 (100) 5 (26)
  Upper respiratory tract infection 11 (58) 0 12 (63) 0 17 (90) 0
  Sinusitis 7 (37) 0 2 (11) 0 7 (37) 0
  Nasopharyngitis 4 (21) 0 2 (11) 0 6 (32) 0
  Urinary tract infection 5 (26) 0 1 (5) 0 5 (26) 0
  Ear infection 3 (16) 0 1 (5) 0 4 (21) 0
 Gastrointestinal disorders 16 (84) 6 (32) 12 (63) 0 17 (90) 6 (32)
  Nausea 12 (63) 2 (11) 3 (16) 0 12 (63) 2 (11)
  Vomiting 11 (58) 1 (5) 1 (5) 0 11 (58) 1 (5)
  Diarrhea 9 (47) 1 (5) 6 (32) 0 10 (53) 1 (5)
  Constipation 5 (26) 0 2 (11) 0 6 (32) 0
  Abdominal pain 3 (16) 1 (5) 2 (11) 0 5 (26) 1 (5)
  Dyspepsia 3 (16) 0 2 (11) 0 4 (21) 0
 Metabolism and nutrition disorders 17 (90) 0 4 (21) 0 17 (90) 0
  Hypercholesterolemia 9 (47) 0 0 0 9 (47) 0
  Hypertriglyceridemia 8 (42) 0 1 (5) 0 8 (42) 0
  Hyperuricemia 7 (37) 0 0 0 7 (37) 0
  Hypokalemia 4 (21) 0 1 (5) 0 5 (26) 0
  Hypomagnesaemia 4 (21) 0 0 0 4 (21) 0
  Musculoskeletal and connective 
tissue disorders 15 (79) 1 (5) 9 (47) 0 16 (84) 1 (5)
  Pain in extremity 7 (37) 0 4 (21) 0 8 (42) 0




Phase 1 (n = 19) Extension (n = 19) Combined (n = 19)
All Grades Grade ≥ 3 All Grades Grade ≥ 3 All Grades Grade ≥ 3
  Back pain 5 (26) 0 3 (16) 0 7 (37) 0
  Muscle spasms 4 (21) 0 1 (5) 0 5 (26) 0
  General disorders and administration 
site conditions 9 (47) 3 (16) 8 (42) 1 (5) 13 (68) 4 (21)
  Fatigue 2 (11) 1 (5) 4 (21) 1 (5) 5 (26) 2 (11)
  Peripheral Edema 4 (21) 0 1 (5) 0 5 (26) 0
 Nervous system disorders 11 (58) 2 (11) 7 (37) 1 (5) 12 (63) 3 (16)
  Headache 6 (32) 1 (5) 3 (16) 0 8 (42) 1 (5)
  Dizziness 5 (26) 0 0 0 5 (26) 0
  Hypoesthesia 4 (21) 1 (5) 0 0 4 (21) 1 (5)
  Respiratory, thoracic, and mediastinal 
disorders 12 (63) 2 (11) 6 (32) 1 (5) 12 (63) 3 (16)
  Cough 5 (26) 0 0 0 5 (26) 0
  Oropharyngeal pain 5 (26) 0 0 0 5 (26) 0
  Skin and subcutaneous tissue 
disorders 9 (47) 1 (5) 7 (37) 0 12 (63) 1 (5)
  Rash 6 (32) 1 (5) 3 (16) 0 8 (42) 1 (5)
 Vascular disorders 10 (53) 3 (16) 3 (16) 0 12 (63) 3 (16)
  Hypertension 4 (21) 3 (16) 1 (5) 0 5 (26) 3 (16)
  Hot flush 2 (11) 0 2 (11) 0 4 (21) 0
 Investigationsc 9 (47) 1 (5) 5 (26) 1 (5) 11 (58) 1 (5)
  Blood and lymphatic system 
disorders 9 (47) 1 (5) 4 (21) 3 (16) 10 (53) 4 (21)
  Thrombocytopenia 5 (26) 0 0 0 5 (26) 0
 Hepatobiliary disorders 8 (42) 1 (5) 3 (16) 0 9 (47) 1 (5)
  Hepatic function abnormal 8 (42) 1 (5) 0 0 8 (42) 1 (5)
  Hyperbilirubinemia 3 (16) 0 3 (16) 0 5 (26) 0
 Renal and urinary disorders 8 (42) 1 (5) 1 (5) 0 9 (47) 1 (5)
  Renal impairment 4 (21) 0 0 0 4 (21) 0
  Injury, poisoning, and procedural 
complications 7 (37) 1 (5) 4 (21) 0 8 (42) 1 (5)
  Reproductive system and breast 
disorders 5 (26) 0 3 (16) 0 8 (42) 0
 Psychiatric disorders 6 (32) 1 (5) 1 (5) 0 7 (37) 1 (5)
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hypertriglyceridemia during the extension study. The overall 
incidence of all-grade hypertriglyceridemia was 0.13 per 
patient-year. Of the 19 patients, 6 (32%) had been receiving 
lipid-modifying therapy prior to the phase 1 study and 9 
(47%) received such therapy during the extension study. 
Two patients reported neutropenia, including 1 grade-3 event, 
during the extension study; the overall incidence of grade-≥3 
neutropenia was 0.01 per patient-year. Thrombocytopenia 
(26%) was reported only during the phase 1 study and with 
no grade-≥3 events. Because hypertriglyceridemia has 
previously been observed in patients who received siltuximab 
[5, 6] or other IL-6-inhibiting agents, such as tocilizumab [10, 
11], and because siltuximab’s mechanism of action involving 
IL-6 blockade may decrease platelet and neutrophil counts in 
patients, mean values over time for triglycerides, neutrophils, 
and platelets were recorded and are shown in Figure 2A–2C. 
Hepatic function abnormalities were reported in 8 (42%) 
patients, including 3 grade-1, 4 grade-2, and 1 grade-3 events 
during the phase 1 study, while none were reported during 
the extension study. Of the 8 patients with hepatic function 
abnormalities, 3 had alanine aminotransferase elevations 
and 4 had aspartate aminotransferase elevations prior to 
receiving siltuximab, while none had abnormal bilirubin 
prior to receiving siltuximab. Three patients had grade-2 
abnormal total bilirubin during the phase 1 study. No patients 
discontinued treatment with siltuximab or had dose delays 
due to hepatic abnormalities.
Efficacy
At the time of extension study start, 1 patient had 
CR, 11 had PR, and 7 had stable disease (SD) based on 
independent review of radiographic images obtained 
during the phase 1 study. During the extension study, 
investigator assessment of disease control was documented. 
All 19 patients continued to have sustained disease 
control, including 8 patients whose treatment interval 
was lengthened from q3wks to q6wks due to established 
prolonged CR. The one additional patient who started in 
the extension study on a q6wks dosing interval showed an 
increase of clinical symptoms and was switched back to 
q3wks dosing after 4 infusions, upon which the symptoms 
resolved. The median duration of disease control from 
the start of the extension study was 1.5 (range 1.4, 1.6) 
years. As such, the overall survival rate in these 19 patients 
following a median of 5.1 years of follow-up in the 
combined phase 1 and extension studies is 100%.
DISCUSSION
We have previously reported on a phase 1 study [5] 
comprising 37 patients with Castleman disease treated 
with the anti-IL-6 monoclonal antibody siltuximab, 
which directly neutralizes IL-6, a key cytokine in the 
pathogenesis of MCD. Nineteen patients experienced 
significant clinical benefit from siltuximab treatment and 
transitioned to an extension study in order to continue 
receiving therapy. Disease control was maintained 
in all patients during the extension study, and with a 
median follow-up of 5.1 (range 3.4, 7.2) years from the 
onset of siltuximab, the overall survival rate of these 
19 patients was 100%, with nearly three quarters of 
patients receiving treatment for longer than 4 years. 
The efficacy of siltuximab in MCD has recently been 
confirmed in an international randomized, double-blind, 
placebo-controlled study [7], which has led to the first 
regulatory approval of siltuximab for MCD in the US 
[8] and European Union [9]. Both in the phase 1 [5] and 
subsequent randomized study [7], in addition to radiologic 
response and symptom control, significant improvement in 
inflammatory markers and normalization of hemoglobin 
and albumin were also noted.
Study periodb
Phase 1 (n = 19) Extension (n = 19) Combined (n = 19)
All Grades Grade ≥ 3 All Grades Grade ≥ 3 All Grades Grade ≥ 3
  Anxiety 5 (26) 1 (5) 0 0 5 (26) 1 (5)
  Depression 4 (21) 0 0 0 4 (21) 0
 Ear and labyrinth disorders 5 (26) 2 (11) 2 (11) 0 6 (32) 2 (11)
 Eye disorders 3 (16) 0 5 (26) 1 (5) 6 (32) 1 (5)
Data presented as n (%).
aReported by ≥ 20% of patients in either phase 1, extension study, or the combined phase 1 and extension studies.
bRefers to study period (CNTO328T03 [phase 1] vs. CNTO328MCD2002 [extension study]) during which the AE(s) 
occurred; “Phase 1” refers to patients enrolled in the phase 1 study who continued on to the extension study.
cRefers to the Medical Dictionary for Regulatory Activities system-organ class category for the names and qualitative 
results (eg, increased, decreased, normal, abnormal, present, absent, positive, negative) of investigations, including clinical 
laboratory test concepts (eg, biopsies), radiologic test concepts, physical examination parameters, and physiologic test 
concepts (eg, a pulmonary function test).
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Figure 2: Clinical laboratory findings (mean ± standard deviation [SD]) over time for the combined phase 1 and 
extension studies. A. triglycerides, B. neutrophils, and C. platelets. Of the 19 extension study patients, 6 (32%) had been receiving lipid-
modifying therapy prior to the phase 1 study and 9 (47%) received such therapy during the extension study.
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The present cohort of patients with MCD received 
a median of 81 (range 49–129) siltuximab doses. Overall, 
siltuximab was well-tolerated, and none of the patients 
discontinued therapy. During the study period of >5 
years, the most common AEs of any grade were upper 
respiratory tract infection, nausea, vomiting, diarrhea, 
and hypercholesterolemia (total cholesterol). Adverse 
events that occurred during the extension study and were 
considered at least possibly attributed to siltuximab included 
pneumonia, tooth abscess, constipation, leukopenia, 
lymphopenia, increased hemoglobin, hypertriglyceridemia, 
hyperbilirubinemia, chronic otitis media, and upper 
respiratory tract infection. Incidence of SAEs was low; 
during the extension study, 1 patient also developed 
a grade-3 SAE, polycythemia, which was considered 
treatment-related. Over time, the blood counts remained 
stable, and no unusual opportunistic infections were 
observed. The overall incidence of grade-≥3 neutropenia 
was 0.01/patient-year, and the incidence of grade-≥3 serious 
infections was 0.02/patient-year. Low-grade elevation of 
total cholesterol and triglycerides was common—47% and 
42%, respectively—but all were manageable with lipid 
modified agents; 6 (32%) patients received lipid-modifying 
agents prior to siltuximab treatment and 9 (47%) received 
them during the extension study. A BMI > 30 was recorded 
in 7 of the 19 patients prior to siltuximab treatment and 
in 8 of 19 patients at the start of the extension study. The 
incidences of AEs occurring ≤2, >2–4, and >4 years after 
initiation of siltuximab therapy were similar, indicating no 
cumulative toxicity. No infusion reactions or development 
of antibodies against siltuximab were noted during this 
extension study. In total, 9 patients were dosed at q6wks 
intervals from the start of the study or switched during the 
study. Eight of them maintained q6wks dosing throughout 
the study. One patient had to return to a q3wks treatment 
interval for symptom control that was maintained with 
continued dosing at q3wks. Per protocol, patients were only 
allowed to receive treatment either q3wks or q6wks.
Of note, these findings are limited in that they 
present on an open-label, single-arm extension study 
offered to patients who were responding to siltuximab 
treatment. Nonetheless, long-term siltuximab 
administration was associated with effective long-term 
disease control with a favorable toxicity profile including 
when administered over years and is an important addition 
to the therapeutic armamentarium for MCD.
MATERIALS AND METHODS
Ethics statement
Investigation has been conducted in accordance with 
the ethical standards and according to the Declaration of 
Helsinki and to national and international guidelines and 
has been approved by the investigators’ institutional review 
boards. All patients provided written informed consent.
Patients
Patients with MCD previously enrolled in the open-
label phase 1 siltuximab study were 18 years or older, 
HIV-negative and HHV-8-negative, and presented with 
active symptomatic MCD. Patients were eligible for the 
extension study if: 1) their disease did not progress while 
receiving siltuximab, 2) they had no clinically significant 
toxicity of grade 2 or higher than the baseline value from 
the phase 1 study, and 3) they received the last siltuximab 
administration within 6 ± 2 weeks before the first study 
extension dose was administered.
Study design
This is an ongoing, open-label, multicenter, single-
arm, phase 2 extension study (NCT01400503) to assess 
the safety of long-term treatment with siltuximab in MCD 
patients who were previously treated in a siltuximab phase 
1 study (NCT00412321). The preplanned safety analysis 
reported here was conducted 21 months after the start of 
patient enrollment in the extension study and includes 19 
patients from the preceding phase 1 siltuximab study.
Patients received siltuximab as a 1-hour intravenous 
infusion at 11 mg/kg every 3 weeks (q3wks). The 
treatment interval could be lengthened to 6 weeks 
(q6wks) at the investigator’s discretion for patients with 
documented radiographic response (confirmed partial 
[PR] or complete [CR] response) for >6 months. Dose 
delays of up to 3 weeks were permitted for management 
and/or resolution of AEs. All patients were treated with 
study agent until they progressed, withdrew consent, or 
experienced unacceptable toxicity.
Study evaluations
Adverse events were graded according to the 
National Cancer Institute Common Terminology Criteria 
for Adverse Events, version 4.0. Physical examinations 
and clinical hematology and chemistry tests were 
performed prior to the cycle 1 dose and every 3 cycles 
thereafter for patients receiving the q3wks regimen or 
every other dosing visit for patients receiving the q6wks 
regimen. Lipid panel analyses were done prior to cycle 
1 dose and every 6 months thereafter. Investigators 
assessed disease control during screening; at cycles 
4, 7, and 10; every 6 months thereafter; and within 4 
weeks following the time of siltuximab discontinuation. 
Laboratory assessments for erythrocyte sedimentation 
rate (ESR), CRP, and fibrinogen were performed at these 
same timepoints. For those who discontinued treatment, 
survival status and subsequent MCD therapies were to 
be collected until the patient was lost to follow-up or 
withdrew consent for the study, until 50% of patients 
died, or until the end of the study—whichever occurred 
first. Survival status will be collected twice a year for 
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patients remaining on study treatment after the 5-year 
data cutoff. For this interim analysis, duration of follow-
up and overall survival—defined as time between the first 
study siltuximab administration and death—are reported. 
Duration of disease control is reported only for the 
duration of the MCD2002 study.
Statistical analysis
Descriptive statistics were used to summarize 
data. No formal hypothesis testing was performed. The 
sample size of this extension study was determined by the 
eligibility of patients transitioning from the phase 1 to the 
phase 2 study and not dictated by statistical calculation. 
Demographics and disease characteristics were reported 
from the phase 1 study [5]. Exposure and safety data from 
the 19 patients who were enrolled in the phase 1 study and 
in the extension study were combined for analysis. Due 
to the long treatment duration, safety analyses included 
both cumulative incidence for all AEs and incidence per 
patient-years of exposure for AEs of clinical interest. 
Efficacy was assessed using central imaging data during 
the phase 1 study and using the investigator’s assessment 
of disease control (specifically, proportions of previously-
responding patients and siltuximab-naïve patients who 
maintained disease control) and duration of disease control 
during the phase 2 extension study.
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